Antengene Corporation Limited products

Diffuse large B-cell lymphoma (DLBCL) is one of the most common types of non-Hodgkin lymphoma (NHL) in adults and a highly heterogeneous malignancy in both clinical manifestations and prognosis. DLBCL accounts for 30%-40% of all NHL cases, and over 40% in most Asian countries.

Multiple myeloma is caused by the dysregulated proliferation of plasma cells, characterized by the proliferation of monoclonal plasma cells that results in an overabundance of monoclonal immunoglobulin or its fragment (M protein). Clinical manifestations of MM include hypercalcemia, renal insufficiency, anemia, and the destruction of the bone. ^1,2 MM primarily occurs in the elderly population. In the Chinese population, MM is the second most common hematologic malignancy, ^3,4 with a median age of onset of 59 years¹ and an incidence rate of 1.46 per 100,000⁴ that is lower than that of western countries. Although MM remains an incurable disease, the introduction of new therapies and diagnostic tools have led to significant advances in the clinical management of MM. The current standard of care therapies for MM include proteasome inhibitors, immunomodulatory agents, monoclonal antibodies and XPO1 inhibitors.

As a next-generation SINE compound that has shown initial signs of a broader therapeutic window,ATG-016 (eltanexor) could potentially enable higher dosing frequency and an extended period of exposure at higher levels. As a result,ATG-016 (eltanexor) may be used to target a wider range of indications. Given the encouraging efficacy and manageable safety profile demonstrated in the ongoing Phase I/II trial conducted by Karyopharm,we plan to conduct a Phase I/II clinical study for MDS as a fast-to-market strategy in China. Since there is no effective treatment option after hypomethylating agents,there are significant unmet medical needs for MDS patients.

ATG-527 (verdinexor) is a SINE compound with a novel dual mechanism of action being developed for the treatment of viral infection. It inhibits the replication of viruses that utilize the XPO1 machinery for some aspect of their life cycle,while contributing to symptom relief via suppression of cytokine-mediated inflammatory responses. Inhibition of XPO1 does not rely on immune status for antiviral effects and may thus benefit immunocompromised patients.